Ramucirumab

Summary

Ramucirumab (CHEMBL1743062) is an approved antibody (ATC L01FG02) targeting KDR; indicated across 44 conditions including non-small cell lung carcinoma and gastric carcinoma; with CIViC clinical evidence for 2 variant-indication associations (e.g. EGFR L858R OR EGFR Exon 19 Deletion in lung non-small cell carcinoma).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L01FG02
• Targets: 1 (KDR)
• Indications: 44 conditions
• Clinical trials: 158
• Precision-oncology evidence (CIViC): 2 variant–indication associations

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743062
Name	Ramucirumab
Type	Antibody
Max phase	4
ATC	L01FG02

Also known as: 1121B, Cyramza, IMC-1121B, LY3009806, Ramucirumab, RAMUCIRUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
KDR	kinase insert domain receptor	Antagonist	10.3	1.1%	P35968

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): KDR.

Top Reactome pathways

7 total, by targets touching each:

Pathway	Targets	Genes
Neuropilin interactions with VEGF and VEGFR	1	KDR
VEGF binds to VEGFR leading to receptor dimerization	1	KDR
Integrin cell surface interactions	1	KDR
VEGFA-VEGFR2 Pathway	1	KDR
VEGFR2 mediated cell proliferation	1	KDR
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB	1	KDR
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	1	KDR

Dominant GO biological processes

GO term	Targets
angiogenesis	1
ovarian follicle development	1
branching involved in blood vessel morphogenesis	1
vasculogenesis	1
positive regulation of protein phosphorylation	1
positive regulation of endothelial cell proliferation	1
lymph vessel development	1
positive regulation of mesenchymal cell proliferation	1
epithelial cell maturation	1
endocardium development	1
endothelium development	1
cell surface receptor protein tyrosine kinase signaling pathway	1
positive regulation of cell population proliferation	1
regulation of cell shape	1
mesenchymal cell proliferation	1

Indications & clinical

Indications

10 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
non-small cell lung carcinoma	4	MONDO:0005233	EFO:0003060
gastric carcinoma	4	MONDO:0004950	EFO:0000178
neoplasm	4	MONDO:0005070	EFO:0000616
gastric adenocarcinoma	4	MONDO:0005036	EFO:0000503
gastric neoplasm	4	MONDO:0021085	EFO:0003897
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
colorectal carcinoma	3	MONDO:0024331	EFO:1001951
urothelial carcinoma	3	MONDO:0040679	EFO:0008528
breast neoplasm	3	MONDO:0021100	MONDO:0007254
colorectal neoplasm	3	MONDO:0005335	MONDO:0005575

27 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
adenocarcinoma	2	MONDO:0004970	EFO:0000228
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
cutaneous melanoma	2	MONDO:0005012	EFO:0000389
melanoma	2	MONDO:0005105	EFO:0000756
carcinoma of esophagus	2	MONDO:0019086	EFO:0002916
carcinoid tumor	2	MONDO:0005369	EFO:0004243
head and neck squamous cell carcinoma	2	MONDO:0010150	EFO:0000181
mesothelioma	2	MONDO:0005065	EFO:0000588
esophageal squamous cell carcinoma	2	MONDO:0005580	EFO:0005922
thymic carcinoma	2	MONDO:0006451	EFO:1000576
intrahepatic cholangiocarcinoma	2	MONDO:0003210	EFO:1001961
squamous cell lung carcinoma	2	MONDO:0005097	EFO:0000708
thymoma	2	MONDO:0006456	EFO:1000581
rectal cancer	2	MONDO:0006519	EFO:1000657
gallbladder neoplasm	2	MONDO:0021253	MONDO:0005411
colonic neoplasm	2	MONDO:0005401	MONDO:0021063
lung carcinoma	2	MONDO:0005138	EFO:0001071
cholangiocarcinoma	2	MONDO:0019087	EFO:0005221
malignant mesothelioma	2	MONDO:0006292	EFO:1000355
lung neoplasm	2	MONDO:0021117	MONDO:0008903
glioblastoma	2	MONDO:0018177	MONDO:0020690
central nervous system cancer	1	MONDO:0002714	EFO:0000326
mantle cell lymphoma	1	MONDO:0018876	EFO:1001469
synovial sarcoma	1	MONDO:0010434	EFO:0001376
non-Hodgkin lymphoma	1	MONDO:0018908	EFO:0005952
desmoplastic small round cell tumor	1	MONDO:0019373	EFO:1000895

7 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 158.

Phase distribution

Phase	Trials
PHASE2	75
PHASE1	33
PHASE1/PHASE2	20
PHASE3	17
PHASE2/PHASE3	7
Not specified	6

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02411448	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT03081143	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy
NCT04704934	PHASE3	ACTIVE_NOT_RECRUITING	Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT05002127	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05096663	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT05633602	PHASE3	ACTIVE_NOT_RECRUITING	Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT06123494	PHASE3	RECRUITING	SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
NCT06203600	PHASE2/PHASE3	RECRUITING	Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06346392	PHASE3	ACTIVE_NOT_RECRUITING	AZD0901 Compared With Investigator’s Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06616584	PHASE2/PHASE3	RECRUITING	Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
NCT00703326	PHASE3	COMPLETED	Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
NCT00917384	PHASE3	COMPLETED	Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
NCT01168973	PHASE3	COMPLETED	A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy
NCT01170663	PHASE3	COMPLETED	A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
NCT01183780	PHASE3	COMPLETED	A Study in Second Line Metastatic Colorectal Cancer
NCT02314117	PHASE3	COMPLETED	A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
NCT02426125	PHASE3	COMPLETED	A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
NCT02435433	PHASE3	COMPLETED	A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
NCT02661971	PHASE2/PHASE3	COMPLETED	FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)
NCT02898077	PHASE3	COMPLETED	A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
NCT02934464	PHASE3	UNKNOWN	Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers
NCT03520946	PHASE3	COMPLETED	RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
NCT04499924	PHASE2/PHASE3	COMPLETED	Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
NCT04675983	PHASE3	TERMINATED	A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)
NCT02678182	PHASE2	ACTIVE_NOT_RECRUITING	Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
NCT02711553	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
NCT03527108	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
NCT03760822	PHASE2	ACTIVE_NOT_RECRUITING	Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
NCT03909334	PHASE2	ACTIVE_NOT_RECRUITING	Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT04069273	PHASE2	RECRUITING	Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
NCT04205968	PHASE2	RECRUITING	Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
NCT04310007	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
NCT04332367	PHASE2	RECRUITING	Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
NCT04340882	PHASE2	ACTIVE_NOT_RECRUITING	Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
NCT04660760	PHASE2	RECRUITING	Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
NCT04921904	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
NCT05642572	PHASE2	RECRUITING	Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
NCT05894824	PHASE1/PHASE2	RECRUITING	T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT05927857	PHASE1/PHASE2	RECRUITING	Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
NCT05980000	PHASE2	ACTIVE_NOT_RECRUITING	Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
NCT05999994	PHASE2	RECRUITING	A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT06007937	PHASE1/PHASE2	RECRUITING	A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
NCT06031688	PHASE2	RECRUITING	Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
NCT06038578	PHASE2	RECRUITING	A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
NCT06043427	PHASE2	RECRUITING	Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
NCT06251973	PHASE2	ACTIVE_NOT_RECRUITING	A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
NCT06445972	PHASE1/PHASE2	RECRUITING	Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06448754	PHASE2	RECRUITING	Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06564298	PHASE2	NOT_YET_RECRUITING	A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
NCT06680622	PHASE2	ACTIVE_NOT_RECRUITING	Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
NCT06771622	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
NCT06996782	PHASE1/PHASE2	RECRUITING	A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338	PHASE2	RECRUITING	A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07546812	PHASE2	RECRUITING	Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
NCT00515697	PHASE2	COMPLETED	A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma
NCT00533702	PHASE2	COMPLETED	A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
NCT00627042	PHASE2	COMPLETED	Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy
NCT00683475	PHASE2	COMPLETED	A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
NCT00721162	PHASE2	COMPLETED	Study of Ramucirumab in Ovarian Cancer
NCT00735696	PHASE2	COMPLETED	A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
NCT00862784	PHASE2	COMPLETED	A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer
NCT00895180	PHASE2	COMPLETED	Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
NCT01017731	PHASE2	COMPLETED	Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
NCT01079780	PHASE2	COMPLETED	Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
NCT01111604	PHASE2	COMPLETED	A Study of Ramucirumab or Icrucumab in Colorectal Cancer
NCT01160744	PHASE2	COMPLETED	A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT01246960	PHASE2	COMPLETED	A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer
NCT01246986	PHASE2	COMPLETED	A Study of LY2157299 in Participants With Hepatocellular Carcinoma
NCT01427933	PHASE2	COMPLETED	A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
NCT01515306	PHASE2	COMPLETED	A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
NCT01567163	PHASE2	COMPLETED	A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
NCT01634555	PHASE2	COMPLETED	A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
NCT01703091	PHASE2	COMPLETED	A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer
NCT01983878	PHASE2	COMPLETED	A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer
NCT02082210	PHASE1/PHASE2	COMPLETED	A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
NCT02213289	PHASE2	COMPLETED	PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
NCT02317991	PHASE2	COMPLETED	Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
NCT02443883	PHASE2	COMPLETED	A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
NCT02514551	PHASE2	COMPLETED	A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
NCT02520141	PHASE2	COMPLETED	Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
NCT02539225	PHASE2	COMPLETED	A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT02581215	PHASE2	COMPLETED	Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
NCT02628951	PHASE2	COMPLETED	Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis
NCT02726399	PHASE2	TERMINATED	Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
NCT02730247	PHASE2	COMPLETED	Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT02795858	PHASE2	COMPLETED	A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
NCT02831491	PHASE2	WITHDRAWN	A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
NCT02999295	PHASE1/PHASE2	COMPLETED	A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
NCT03008278	PHASE1/PHASE2	COMPLETED	Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
NCT03141034	PHASE2	COMPLETED	Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
NCT03281369	PHASE1/PHASE2	COMPLETED	A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
NCT03502746	PHASE2	TERMINATED	Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
NCT03560973	PHASE2	COMPLETED	A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM
NCT03650764	PHASE1/PHASE2	COMPLETED	Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT03686488	PHASE2	COMPLETED	TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT03689855	PHASE2	COMPLETED	Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC
NCT03694002	PHASE2	COMPLETED	Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
NCT03704077	PHASE2	WITHDRAWN	An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
NCT03739801	PHASE1/PHASE2	WITHDRAWN	MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
NCT03745430	PHASE1/PHASE2	COMPLETED	RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Clinical evidence (CIViC)

Variant × indication × effect (2 predictive associations from 2 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
EGFR L858R OR EGFR Exon 19 Deletion	Lung Non-small Cell Carcinoma	Sensitivity/Response	Erlotinib + Ramucirumab	CIViC A	EID11240
ERBB2 Overexpression	Gastroesophageal Junction Adenocarcinoma	Reduced Sensitivity	Ramucirumab	CIViC B	EID7064

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

161 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	KDR
PAZOPANIB	ChEMBL + PubChem	Phase 4 (approved)	KDR
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	KDR
ABEMACICLIB	ChEMBL	Phase 4 (approved)	KDR
ABROCITINIB	ChEMBL	Phase 4 (approved)	KDR
ACALABRUTINIB	ChEMBL	Phase 4 (approved)	KDR
ALECTINIB	ChEMBL	Phase 4 (approved)	KDR
AUROTHIOGLUCOSE	ChEMBL	Phase 4 (approved)	KDR
AXITINIB	ChEMBL	Phase 4 (approved)	KDR
BRIGATINIB	ChEMBL	Phase 4 (approved)	KDR
CABOZANTINIB	ChEMBL	Phase 4 (approved)	KDR
CABOZANTINIB S-MALATE	ChEMBL	Phase 4 (approved)	KDR
CERITINIB	ChEMBL	Phase 4 (approved)	KDR
CRIZOTINIB	ChEMBL	Phase 4 (approved)	KDR
DASATINIB	ChEMBL	Phase 4 (approved)	KDR
ENASIDENIB	ChEMBL	Phase 4 (approved)	KDR
ENTRECTINIB	ChEMBL	Phase 4 (approved)	KDR
ERDAFITINIB	ChEMBL	Phase 4 (approved)	KDR
ERLOTINIB	ChEMBL	Phase 4 (approved)	KDR
ESTRAMUSTINE	ChEMBL	Phase 4 (approved)	KDR
FEDRATINIB	ChEMBL	Phase 4 (approved)	KDR
FOSTAMATINIB DISODIUM	ChEMBL	Phase 4 (approved)	KDR
FRUQUINTINIB	ChEMBL	Phase 4 (approved)	KDR
FUTIBATINIB	ChEMBL	Phase 4 (approved)	KDR
GEFITINIB	ChEMBL	Phase 4 (approved)	KDR
GLAFENINE	ChEMBL	Phase 4 (approved)	KDR
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	KDR
IBRUTINIB	ChEMBL	Phase 4 (approved)	KDR
IMATINIB	ChEMBL	Phase 4 (approved)	KDR
INDIGOTINDISULFONATE	ChEMBL	Phase 4 (approved)	KDR
INFIGRATINIB	ChEMBL	Phase 4 (approved)	KDR
ISOXICAM	ChEMBL	Phase 4 (approved)	KDR
LENVATINIB	ChEMBL	Phase 4 (approved)	KDR
MEBENDAZOLE	ChEMBL	Phase 4 (approved)	KDR
MESALAMINE	ChEMBL	Phase 4 (approved)	KDR
MIDOSTAURIN	ChEMBL	Phase 4 (approved)	KDR
NERATINIB	ChEMBL	Phase 4 (approved)	KDR
NICLOSAMIDE	ChEMBL	Phase 4 (approved)	KDR
NINTEDANIB	ChEMBL	Phase 4 (approved)	KDR
NINTEDANIB ESYLATE	ChEMBL	Phase 4 (approved)	KDR
NOVOBIOCIN	ChEMBL	Phase 4 (approved)	KDR
OLMUTINIB	ChEMBL	Phase 4 (approved)	KDR
OLSALAZINE	ChEMBL	Phase 4 (approved)	KDR
OSIMERTINIB	ChEMBL	Phase 4 (approved)	KDR
PEXIDARTINIB	ChEMBL	Phase 4 (approved)	KDR
PHENYL AMINOSALICYLATE	ChEMBL	Phase 4 (approved)	KDR
PIPERAZINE	ChEMBL	Phase 4 (approved)	KDR
PONATINIB	ChEMBL	Phase 4 (approved)	KDR
QUIZARTINIB	ChEMBL	Phase 4 (approved)	KDR
SELPERCATINIB	ChEMBL	Phase 4 (approved)	KDR
SORAFENIB	ChEMBL	Phase 4 (approved)	KDR
SORAFENIB TOSYLATE	ChEMBL	Phase 4 (approved)	KDR
STIRIPENTOL	ChEMBL	Phase 4 (approved)	KDR
SUNITINIB	ChEMBL	Phase 4 (approved)	KDR
SUNITINIB MALATE	ChEMBL	Phase 4 (approved)	KDR
TIVOZANIB	ChEMBL	Phase 4 (approved)	KDR
TOFACITINIB	ChEMBL	Phase 4 (approved)	KDR
UPADACITINIB	ChEMBL	Phase 4 (approved)	KDR
VANDETANIB	ChEMBL	Phase 4 (approved)	KDR
VEMURAFENIB	ChEMBL	Phase 4 (approved)	KDR
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	KDR
ADEMETIONINE	ChEMBL	Phase 3	KDR
ALISERTIB	ChEMBL	Phase 3	KDR
BARASERTIB	ChEMBL	Phase 3	KDR
BRIVANIB	ChEMBL	Phase 3	KDR
CANERTINIB	ChEMBL	Phase 3	KDR
CATEQUENTINIB	ChEMBL	Phase 3	KDR
CEDIRANIB	ChEMBL	Phase 3	KDR
CEP-1347	ChEMBL	Phase 3	KDR
DEFACTINIB	ChEMBL	Phase 3	KDR
DOVITINIB	ChEMBL	Phase 3	KDR
FAMITINIB	ChEMBL	Phase 3	KDR
LESTAURTINIB	ChEMBL	Phase 3	KDR
LINIFANIB	ChEMBL	Phase 3	KDR
MOTESANIB	ChEMBL	Phase 3	KDR
ORANTINIB	ChEMBL	Phase 3	KDR
QUERCETIN	ChEMBL	Phase 3	KDR
RADOTINIB	ChEMBL	Phase 3	KDR
RIVOCERANIB	ChEMBL	Phase 3	KDR
SARACATINIB	ChEMBL	Phase 3	KDR
SEMAXANIB	ChEMBL	Phase 3	KDR
SITRAVATINIB	ChEMBL	Phase 3	KDR
SURAMIN	ChEMBL	Phase 3	KDR
SURUFATINIB	ChEMBL	Phase 3	KDR
THIMEROSAL	ChEMBL	Phase 3	KDR
VANIPREVIR	ChEMBL	Phase 3	KDR
VATALANIB	ChEMBL	Phase 3	KDR
AEE-788	ChEMBL	Phase 2	KDR
AG-13958	ChEMBL	Phase 2	KDR
ALTIRATINIB	ChEMBL	Phase 2	KDR
ANTHRALIN	ChEMBL	Phase 2	KDR
AT-9283	ChEMBL	Phase 2	KDR
AZD-3759	ChEMBL	Phase 2	KDR
AZM-475271	ChEMBL	Phase 2	KDR
BEMCENTINIB	ChEMBL	Phase 2	KDR
BFH-772	ChEMBL	Phase 2	KDR
BMS-777607	ChEMBL	Phase 2	KDR
CEFAZEDONE	ChEMBL	Phase 2	KDR
CENISERTIB	ChEMBL	Phase 2	KDR
CEP-11981	ChEMBL	Phase 2	KDR